Mass cytometry further revealed that YW3-56 treatment simultaneously suppresses leukemia stemness (CD44/CD133 downregulation) and promotes myeloid differentiation (CD11b/CD14 upregulation), as well as enhances immunogenic activation (CD80/CD86 increase). Here, CD80 is linked to leukemia.